Ionis Pharmaceuticals (NASDAQ: IONS) reported Q4 EPS of ($0.66), $0.45 better than the analyst estimate of ($1.11). Revenue for the quarter came in at $227 million versus the consensus estimate of $135.58 million.

GUIDANCE:

Ionis Pharmaceuticals sees FY2025 revenue of ~$600 million, versus the consensus of $677.1 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.